Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

L.A. McKeown

October 23, 2019

News Daily News

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Michael O'Riordan

October 22, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Conference News ESC 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Caitlin E. Cox

September 06, 2019

News Conference News ESC 2019

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Michael O'Riordan

September 02, 2019

News Conference News ESC 2019

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Shelley Wood

August 31, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Todd Neale

June 26, 2019

News Daily News

To Battle CVD in China, the ‘Healthcare Pyramid’ Must Be Flipped

L.A. McKeown

June 25, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Daily News

Risk Prediction Tool Shows Promise for Detecting Heart Failure Earlier

L.A. McKeown

May 13, 2019

News Daily News

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Yael L. Maxwell

April 18, 2019

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

L.A. McKeown

April 03, 2019

News Conference News ACC 2019

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

Michael O'Riordan

March 17, 2019

News Daily News

New Equations Help ID Patients at Low Risk for Bleeding With Aspirin

Michael O'Riordan

February 26, 2019

News Daily News

Aspirin as Primary Prevention Curbs CV Events but Ups Major Bleeding, Too: Meta-analysis

Caitlin E. Cox

January 24, 2019

Advertisement

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Recurrent Events Common Among Young Patients With CAD

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

To Battle CVD in China, the ‘Healthcare Pyramid’ Must Be Flipped

CHD Mortality Significantly Elevated in Patients With Severe FH

Risk Prediction Tool Shows Promise for Detecting Heart Failure Earlier

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

New Equations Help ID Patients at Low Risk for Bleeding With Aspirin

Aspirin as Primary Prevention Curbs CV Events but Ups Major Bleeding, Too: Meta-analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content